Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SCN1A | P35498 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5661980 | 0.98 | KEAP1 (0.58) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL11086 | 0.93 | KEAP1 (0.58) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL14969239 | 0.91 | KEAP1 (0.52) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL5858928 | 0.91 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL5858233 | 0.91 | KEAP1 (0.56) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL11299 | 0.84 | — | — | |
| SCHEMBL1998867 | 0.84 | KEAP1 (0.71) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL7239607 | 0.84 | KEAP1 (0.71) | KEAP1SMN1; SMN2HPGDDUSP3GLA | |
| SCHEMBL4376062 | 0.83 | SMN1; SMN2 (0.48) | KEAP1SMN1; SMN2HPGDDUSP3KDM4E | |
| SCHEMBL5662662 | 0.82 | KDM4E (0.56) | KEAP1SMN1; SMN2HPGDDUSP3GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936487-B | Compounds for the treatment of kinase dependent disorders | 埃克塞里艾克西斯公司 | 2024-07-09 | — | — | CN | claimed |
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. | 2024-05-16 | — | — | US | claimed |
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2024-05-09 | — | — | US | claimed |
| WO-2024054832-A1 | CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | claimed |
| CN-114555602-B | Heterocyclic compounds as STING modulators | 百济神州有限公司 | 2024-02-06 | — | — | CN | claimed |
| CN-111606887-B | Novel kinase inhibitor | 安徽中科拓苒药物科学研究有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-3670490-B1 | METHOD OF PURIFYING PINE CHEMICAL COMPOSITIONS FROM ALDEHYDES | KRATON POLYMERS LLC (US) | 2023-01-18 | — | — | EP | claimed |
| CN-110437220-B | Triazole compound and application thereof | 暨南大学 | 2022-12-27 | — | — | CN | claimed |
| CN-115403557-A | Quinoline and quinazoline compounds as fourth-generation EGFR (epidermal growth factor receptor) inhibitor and application thereof | 华东理工大学 | 2022-11-29 | — | — | CN | claimed |
| WO-1996033980-A1 | QUINAZOLINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-10-31 | — | — | WO | claimed |
| WO-1996028448-A1 | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-09-19 | — | — | WO | claimed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | claimed |
| WO-1996015118-A1 | ANILINE DERIVATIVES | ZENECA LIMITED (GB) | 1996-05-23 | — | — | WO | claimed |
| US-5516915-A | Bis-(1H-indol-3-yl)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them | GOEDECKE AKTIENGESELLSCHAFT (DE) | 1996-05-14 | — | — | US | claimed |
| EP-0370236-B1 | INDOLOCARBAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-12-27 | — | — | EP | claimed |
| EP-0362695-B1 | PYRROLOCARBAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1991-04-03 | — | — | EP | claimed |
| EP-0397060-A2 | Maleinimide derivatives and their use as medicines | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-11-14 | — | — | EP | claimed |
| EP-0370236-A1 | Indolocarbazole derivatives, processes for their preparation and their use as medicaments | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-05-30 | — | — | EP | claimed |
| EP-0362695-A1 | Pyrrolocarbazole derivatives, processes for their preparation and their use as medicaments | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1990-04-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158370-A1 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | CKS1B, CKS2, MARK1 | KEAP1 1057/4885SMN1; SMN2 2663/4885HPGD 2335/4885 |
| US-20240150371-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | ERBB2, MAP3K6, PRKCH | KEAP1 663/4885SMN1; SMN2 1437/4885HPGD 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.